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Abstract 
As described initially from clinical and experimental studies, P-glycoprotein (P-gp) plays a central role in the 
pharmacoresistance of epilepsy, acting by efflux of AEDs mainly at blood brain barrier (BBB) level. However, 
repetitive seizures can produce both brain and heart P-gp overexpression. Because P-gp activity induces 
membrane depolarization, its neuronal expression could be acting in the intrinsic mechanism of 
epileptogenesis, and its heart expression, can be a high risk factor of death, after severe-continuo 
convulsive stresses as in  fatal status epilepticus or in SUDEP. Additionally, because P-gp is also a stem cell 
marker, we suggests that its constitutive overexpression in dysplastic neurons from brain epileptogenic 
areas observed in patients with refractory epilepsies, should be addressed as a risk factor of seizures 
relapse after surgical treatment. Here we discuss these concepts, based on our own clinical and 
experimental experiences, and reviewing the current literature on these subjects.  
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“What is a seizure and what is epilepsy?” 
Seizures and epilepsy are not the same. It is defined that seizure as “the abnormal excessive or 
synchronous neuronal activity in the brain” that can be produced secondary to a wide spectrum of injuries. 
However, “epileptic seizures” are produced spontaneously, so, a seizure is an event and epilepsy is a 
disorder involving recurrent unprovoked seizures. After several years of deliberations on this issue have 
now been published the result from International League Against Epilepsy (ILAE) commissioned second 
task force, to develop a practical (operational) definition of epilepsy, designed for use by doctors and 
patients [1], and adopted as a position of the ILAE. Some comments were published to better 
understanding of this definition, however, it is limited to a observational clinical level [2,3], and not 
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describe the cellular or sub-cellular mechanistic process that involve alterations on functional properties of 
the neuronal membrane.   
Epilepsy is the second most common neurological disorder after cerebrovascular accident (CVA) or 
stroke, and it is estimated that approximately ~1.0-2.0 % of the population is affected by different forms of 
epilepsy. Interestingly, near 30 % of epilepsies, have identifiable injuries to the brain that triggered the 
development of the named symptomatic epilepsies [4]. So, a non-specific damaging factor producing a 
brain injury can develop symptomatic epilepsy after a very complex subclinical process, which links this 
mentioned first insult with the clinically expressed first spontaneous epileptic seizure. And this particular 
and multifactorial process is recognized as latency phase or “epileptogenesis”.  
This cellular/molecular phenomenon is started after the brain injury and can be facilitated by some 
conditions as age, co-morbidity, medications, etc. Blood brain barrier (BBB) damage, angiogenesis, gliosis, 
inflammation, axonal sprouting or injury, acquired channelopathies, and changes of dendritic plasticity, are 
some of long list of modifications observed during this latency phase. Because a wide spectrum of different 
forms of brain injuries can lead in a secondary epileptic syndrome, it is important to add that the presence 
of background genes, developmentally regulated genes and/or epigenetic factors, can play a role in these 
process. Perhaps, stroke, brain hypoxia and/or status epilepticus are the more clear conditions that can 
develop secondary epilepsy as well as to disclose a refractory phenotype [5]. 
Neuronal excitability can arise from structural/functional changes at the postsynaptic membrane level, 
alterations in the type, number, and distribution of voltage- and ligand-gated ion channels or biochemical 
modification of receptors that increase permeability to Ca2+, favoring development of the prolonged 
depolarization that precedes seizures. Excessive excitation is the key factor underlying ictogenesis, which 
may originate from individual neurons, the neuronal environment, or neuronal networks [6]. The 
imbalance between the excitatory (high) and the inhibitory (reduced) stimuli are the main mechanism of 
neuronal membrane depolarization and the onset of seizures.  
Neuronal axons have a resting membrane potential of about -70 mV inside vs outside. Action potentials 
occur due to net positive inward ion fluxes, resulting in local changes in the membrane potential. 
Membrane potentials vary with the activation of either ligand- or voltage-gated ion channels, which are 
affected by changes in either the membrane potential or intracellular ion concentration. When a neuron is 
at -70 mV it is said to be at resting potential. Here, a neuron is not being excited by anything and is 
basically asleep, awaiting input from other neurons. Resting potential is maintained by the sodium-
potassium pump, which constantly pushes sodium out of the neuron. The pump operates via a bunch of 
sodium-potassium transporters located along the membrane. These transporters push three sodium 
molecules out for every two potassium molecules it takes in. Resting potential exists when sodium is on 
the outside of the cell and potassium is on the inside. 
When a neuron is excited the membrane potential shoots from -70 mV to about 40 mV and the 
membrane is depolarized. The excitability of synaptic terminals depends on the amount of excitatory 
neurotransmitter released (e.g., glutamic acid or activation of glutamergic receptors) as well as of an 
insufficient amount of inhibitor neurotransmitter released (e.g., γ-aminobutyric acid, or GABA), and 
consequently of the final extent of membrane depolarization produced. Interestingly, through the axis 
glutamate/NMDA receptor/cyclooxygenase-2 (COX-2) signaling, glutamate can induces overexpression of 
P-glycoprotein (P-gp) in brain [7,8]. The efflux of drugs by the multidrug transporters, particularly P-gp 
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(ABCB1-transporter) is one of the principal means by which several patients with pharmacoresistant 
epilepsy develops refractoriness to a wide spectrum of antiepileptic drugs (AEDs) [9,10]. 
The questions are how so different factors and cellular/molecular process underlying during brain 
injury, can induce an enduring phenomenon with chronically recurrent seizures and why persistent 
(without control) convulsive stress is a main risk factor of develop pharmacoresistant epilepsy? So, is the 
acquired refractoriness an inducible process? 
ABC-transporters: P-glycoprotein 
The movement of different compounds as solutes, nutrients, ions, toxics or drugs across cell 
membranes is a critical biological process where the ATP-binding cassette (ABC) transporter´s family plays 
a central role and represents one of the largest families of transport proteins [11-13]. Several functional 
properties of these transporters have been described and their importance is indicated not only by the 
large number of encoding genes, or their ubiquitous expression, but also by their ancestral origin and 
because 22 of 48 human ABC proteins are implicated in human diseases [14]. The presence of these pumps 
in the liver, bowel, and kidney and BBB suggests that these transport systems have evolved to protect the 
organism against, endogenous/circulating chemicals, xenobiotics, organic ions, and drugs [15]. 
Particularly the P-gp was the first eukaryotic ABC-transporter identified conferring multidrug resistance 
to cancer cells [16,17]. P-gp has a molecular architecture with a core structure of two pairs of domains of 
nucleotide binding domain (NBD) where ATP is hydrolyzed and the transmembrane domain (TMD) that 
consists of six transmembrane helices and where is the drug- binding site. 
The mechanistic way of drugs transport is based on conformational changes at the NBDs level, 
transmitted to the TMDs, and producing the drug export that is energy ATP-dependent [18,19]. An 
‘‘alternating catalysis model’’ have been described indicating that after ATP hydrolysis, ADP could be 
trapped at one of two NBDs.  
Normally, in the absence of nucleotide (state I), the two opposing domains of the ATP sites are in the 
‘‘open’’ conformation, and the binding of two molecules of ATP results in the formation of the nucleotide 
sandwich (state II) that draws together the opposing faces of the ATP sites. This is followed by a 
conformational change in which one of the two ATPs is ‘‘occluded’’ in a non-exchangeable form (state III) 
(Figure 1)[20].  
ABC-transporters in the brain 
The central nervous system (CNS) effects of many therapeutic drugs are blunted because of 
restricted entry into the brain. The basis for this poor permeability is the brain capillary endothelium, 
which comprises the BBB. This tissue exhibits very low paracellular (tight junction, or TJ) permeability and 
expresses a potent system of drug export pumps. The BBB is a highly specialized structural and biochemical 
barrier that regulates the entry of blood-borne molecules and cells into the brain and preserves ionic 
homeostasis within the brain microenvironment.  
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Figure 1: Drug efflux cycle: the drug binds first to the TMD producing conformational changes of 
ABC-transporter. a) State I: The inactive structure of P-gp. b) State II: The inward-facing 
conformation. c) State III: The outward-facing conformation 
 Transporters are abundantly expressed in the brain, mainly in the vascular endothelial cells (VEC) of 
the BBB, the epithelial cells of the brain-cerebrospinal fluid barrier (BCSFB), and also some parenchyma 
cells in brain, particularly in the food-ending process of astrocytes-touching VEC of vessels. Drug uptake 
into the brain highly depends on the efflux transporters expressed at both BBB and BCSFB biological barrier 
systems. 
 A polarized location of the drug efflux transporters is mainly present on the luminal (apical or 
blood) side of the endothelial cells in the brain capillary where P-gp, BCRP, and MRP2 are unequivocally 
expressed at the blood side. This natural distribution of the main drug-transporters at BBB, indicates that 
the normal presence of some ABC-transporters (including P-gp) at BBB level, is not enough to produce the 
impairment of AEDs entrance in the brain for the responders patients. The “transporter`s hypothesis” to 
explain the refractoriness in epilepsy need not only a functional up-regulation of these transporters at BBB 
level to clean/export AEDs, but also they should be expressed on previously non-expressing cell as neurons. 
The inducible properties of these transporters as well as the the pharmacoresistant phenotype [9] links 
pharmacoresistance with epileptogenesis, as discussed below. 
P-glycoprotein and drug resistant phenotype in epilepsy 
One-half of newly diagnosed patients with epilepsy obtain full seizure control with the first AED trial, 
and 13 % more enter remission with the addition of a second drug. However, the 30-40 % of the remaining 
patients are not to obtain satisfactory seizure control in spite of different drug combinations.  
It is clear the wrong choice of AEDs may be the cause of treatment failure. However, with the correct 
therapeutic stratagem, Sanjay M. Sisodiya (2006) suggests that patients, who were considered drug 
resistant, may not remain so as newer AEDs are developed or designed to new target previously 
unappreciated underlying pathophysiological mechanisms. Additionally, he suggests that for individuals 
who we could define as being drug resistant, perhaps their epilepsy is considered “drug resistant” simply 
because we do not yet have the appropriate drugs for the treatment [21]. However, in spite of the 
increased amount of new AEDs developed during the last 30 years, the same percentage (30-40 %) of 
pharmacoresistant patients remains without modifications (Fig. 2). 
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Figure 2: The increase of new AEDs not decrease the percentage of drug-resistant cases (Modified 
from Czornyj & Lazarowski: Genetics of Epilepsy and Refractory Epilepsy. Ed. Michael Dean. 
COLLOQUIUM SERIES ON THE GENETIC BASIS OF HUMAN DISEASE, Morgan & Claypool Life Sciences, 
2013) 
After the initial descriptions of the potential association between P-gp overexpression in the brain and 
refractory epilepsy [22,23], several other groups have reported high levels of P-gp expression in 
epileptogenic brain specimens from patients with refractory epilepsy. In these studies, P-gp was highly 
expressed not only in endothelial cells of BBB but also in brain parenchymal cells [9,10,24-26]. 
Similar results were observed by independent experimental studies of different epileptic models, such 
as a single dose of intra-cerebroventricular kainic acid, chronic epilepsy, repetitive PTZ-induced seizures 
and pilocarpine-induced status epilepticus. In these studies, seizure-induced overexpression of P-gp at BBB 
and brain parenchyma cells as astrocytes and neurons were described [25,27-29]. Furthermore, after 
repetitive induced seizures, the simultaneous high P-gp expressions in different brain regions and liver or 
heart have been reported [30,31].  
P-glycoprotein and pharmacokinetics alterations 
Refractory epilepsy is described in patients receiving recommended AEDs doses, have an adequate 
therapeutic levels of AEDs in plasma, but remains without control of seizures. It was demonstrated that 
therapeutic levels of phenytoin (PHT) in blood and CSF can be achieved independently of the route of 
administration, as long as conventional loading doses are used, and in the case of PHT i.v. administration, 2 
h are enough to reach steady state concentrations within the therapeutic range [32].  As previously 
described in two cases reports [23,33], patients can have persistent low plasmatic levels of at least one of 
the AEDs administered, despite their scrupulous compliance with the prescribed drugs regimen. Often, 
laboratory professionals and physicians have no rational explanations, and non-detectable errors in AED 
measurement procedures and methods are assumed. Most AEDs are substrates of P-gp, and the inducible 
nature of this ABC-transporter gene suggests that over-expression of this protein can be observed in all 
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excretory organs including BBB, playing a critical role in the modification of both systemic and local 
pharmacokinetics of AEDs.  
Experimentally, it was also demonstrated that brain P-gp overexpression, correlated with the lower 
hippocampal phenytoin concentration in a refractory epileptic model, and whereas the administration of 
an antagonist of P-gp such as nimodipine (2 mg/kg) restored the normal central PHT pharmacokinetics 
[34].   
Clinically and experimentally, the uses of some calcium channel blockers have been described to 
increase plasmatic levels of AEDs simultaneously with the recovery of seizures control [35,36].  
It is known that ABC-transporters are located at the apical membrane of both acinar and ductal cells 
[37]. Those proteins are important determinants of interindividual differences in intestinal absorption or 
hepatic clearance, and hence plasma levels of some if not all AEDs.  These variations can also be detected 
by measurement of saliva drug concentration, and it is sensitive enough for detecting systemic clearance 
changes. Furthermore, some AEDs would modify their bioavailability and clearance by inducing efflux 
transporter throughout chronic treatments, from the first dose to multiple dose administration and it can 
be documented by saliva drug concentrations. It is important to notice the usefulness of salivary drug 
concentrations to determine systemic clearance in patients not only from a pharmacokinetic point of view 
but also as new index to phenotype epileptic patients as refractory to the pharmacological treatment [38]. 
Iannetti et al. [39] recently described 11-years-old boy who developed status epilepticus, after a 
prolonged right-side simple partial motor seizure, which was unresponsive to long term aggressive 
treatment with several AEDs. Control of convulsive seizures was achieved at valproic acid plasma level of 
108 μg/ml, but electrical status epilepticus persisted, and the child remained comatose. On day 37, a 
treatment with verapamil (blocker of calcium L-channel and P-gp) was started and 1.5 hour after the 
initiation the infusion, the patient regained consciousness, was able to breathe spontaneously, and the 
status epilepticus, promptly disappeared. The authors suggested that verapamil, a known P-gp inhibitor 
acted by facilitating the brain penetration of AEDs simultaneously administrated to the patient. 
Role of P-glycoprotein in epileptogenesis  
Taking in account that in a normal brain, neurons do not express P-gp, which could be the functional 
changes in neurons expressing P-gp,? 
Approximately one third of patients with epilepsy do not have satisfactory control of seizures with 
antiepileptic drugs (AEDs) and it is suggested that drug resistant phenotype could be present at the early 
stage of the disease [40].  
At present, antiepileptic drug refractoriness has been explained by the “reduced drug-target sensitivity” 
and the “drug transporter overexpression” hypotheses. 
MDR-1 gene upregulation could be acquired as a consequence of repetitive non-controlled seizures 
[28,29] as well as secondary to pathological conditions such as inflammation, tumors or hypoxia [41-44], 
supporting the idea that silent mechanisms could overexpress P-gp in brain before epilepsy and 
refractoriness becomes clinically evident. Repetitive seizures, status epilepticus as well as brain hypoxia 
induces P-gp expression in neurons. This P-gp induced expression depends on the frequency and intensity 
of seizures and is related to a progressive increase of the pharmacoresistant phenotype [45]. Furthermore, 
the induced “de novo” expression of P-gp in previously non-expressive cells as observed particularly in 
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neurons from epileptogenic brain areas, suggests a differential role of this transporter, perhaps related to 
the intrinsic convulsive mechanism [29,33,46].  
In this regard, a group of evidence indicates that P-gp can also decrease the plasma membrane 
potential of several cell types [47,48] and modify swelling-activated Cl
−
 currents [49], both physiologic 
disturbances observed during brain hypoxia [50] and convulsive stress [51]. According to these 
observation, recently was reported the first study demonstrating that daily PTZ-induced seizures produces 
simultaneously the progressive acquisition of pharmacoresistant phenotype, increased brain P-gp 
expression and high membrane depolarization in brain areas such as hippocampus and cortex [52]. In this 
study, the recovery of potential membrane of depolarized slides in hippocampus and neocotex (in vitro 
experiments) was induced when PHT was combined with nimodipine, a calcium channel blocker that also 
inhibit P-gp function. 
In addition to the much known drug pump model, some studies indicate that P-gp may mediate drug 
resistance through channels function regulation [53]. Supporting this idea, it has been described that MDR1 
protein behaves as some type of Cl- transporter, stimulates Cl- channel activity and may alter cell volume in 
several cell types [54]. Its overexpression leads to decreased plasma membrane electrical potential by 
increasing Cl
-
 permeability and thus decreasing the dominance of membrane potential by K
+
 conductance, 
and leads to altered pHi regulation [47,48]. So, brain P-gp overexpression could contribute to crucial 





 exchange [55], enhanced extracellular concentration of potassium [56], and particularly in the 
increased membrane depolarization [57].  
Considering all the mentioned evidences, the popular comments saying that “seizures induce seizures” 
and “seizures without control induce refractoriness” could have a mechanistic and molecular explanation, 
where progressive and induced P-gp expression in neurons reduces the membrane potential and the 
seizure thresholds, and increasing the risk of pharmacoressitance. Consequently, how much time P-gp can 
be expressed in brain cells after an initial inducer insult?  
 
Figure 3: Neuronal expression of P-gp (white arrow) can be induced by seizures, hypoxia, inflammation, drugs, 
cytokines, tumors, metabolic disorders, toxics, trauma, or infections. Irrespective which was the cause, in these 
conditions neuronal membranes will be depolarized. Interestingly, all these mentioned factors are the more common 
conditions that develop acquired epilepsy. 
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The time course for the expression of P-gp in astrocytes after status epilepticus following 
intracerebroventricular kainate injection, was 10 consecutive weeks [25], and after the cortical 
devascularization inducing focal hypoxia, P-gp expression in neurons was maximal at day 7, and remained 
lightly positive at day 28 [58]. P-gp could be expressed longer times depending on the severity and also the 
frequency of the repetitive inducer stimulus. So, we can speculate that time during neuronal P-gp remains 
expressed, results in a pharmacoresistant window, or the time during the patients have higher risk to get a 
new seizures, or both conditions. If it is the case, pharmacoresistance and epileptogenesis are sharing the 
same mechanistic risk factor: “P-gp expressed in neurons”. 
P-glycoprotein and Sudden Unexpected Death in Epilepsy (SUDEP) 
Patients with Refractory Epilepsy carry an increased mortality risk of that is more elevated than 
in patients with well-controlled seizures. The sudden, unexpected, witnessed or unwitnessed, no traumatic 
and no drowning deaths in patients with epilepsy, is usually a clinical phenomenon in which post-mortem 
examination does not reveal a toxicological or anatomical cause of death [59]. The clinical characteristics of 
patients with epilepsy at particular risk for SUDEP are related with a long history (more than 15 years) of 
pharmacoresistant epilepsy or high seizure frequency (more than 15 seizures/moth). All these patients 
currently receive antiepileptic drug (AED) polypharmacy, and commonly changes between different 
therapeutic combinations and/or doses. Persistent low levels of AEDs in plasma as well as poor adherence 
to pharmacotherapy are also observed in these patients, and several of all of these features are associated 
to pharmacoresistant epilepsy [60].     
 Different studies have suggested that seizure activity as inducer of cardiovascular alterations, 
changes in the respiratory rate including tachypnea, hypopnea or apnea, related also with heart ischemia, 
suggesting that respiratory and mainly cardiovascular abnormalities during and between seizures, could 
play a central role in SUDEP [61-63]. It was also experimentally demonstrated that after both acute or 
chronic heart hypoxia, P-glycoprotein results to be overexpressed in cardiomyocytes and associated with 
heart stunning [64,65].  
According with these observations it is important notice that continuous convulsive stress could mimic a 
repetitive apneas or hypoxia and produce heart ischemia. In bases to these considerations, the progressive 
and simultaneous P-gp overexpression in brain and heart, related with the development of fatal status 
epilepticus after experimental repetitive seizures was recently demonstrated by our group [66]. 
Furthermore, we can speculate that high P-gp expression in brain, particularly in neurons (as previously 
described above), could play a role on the risk for SE development, and high P-gp expression in heart could 
play a role in the risk for develop an acute and fatal heart failure.  
P-gp as stem cell marker of brain malformation/tumor refractory epilepsies and/or relapsing marker 
after surgical treatment 
Several malformations of cortical development as well as brain tumors are associated with refractory 
epileptic syndromes and/or developmental delay. The main developmental brain abnormalities identified 
are hemimegalencephaly, polymicrogyria, agyria-pachygyria, schizencephaly, heterotopic gray matter, 
transmantle dysplasia, focal cortical dysplasia, or cortical tubers. P-gp and others ABC-transporters have 
been reported to be over-expressed in these malformations of cortical development and brain cortical 
tubers explaining why all of them are clinically characterized by phamacoresistant phenotype 
[22,23,67,68]. Epilepsy is also common disorder in patients with brain tumors and can substantially affect 
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daily life, even if the tumor is under control. In these cases, multidrug-ABC-transporters expressed at blood 
brain barrier, brain tumor cells and tumor-surrounding cells, prevent the access of antiepileptic drugs into 
brain parenchyma, and patients develop a refractory phenotype.  
In Subependimmal Giant Astrocytoma (SEGA), ABC-transporters (P-gp and BCRP) and CD34 stem cell 
markers were highly expressed in non-vascularized tumor cells. Heterogeneous distributions for these 
markers were detected with differential immunostaining pattern, showing high immunoreactivity in SEGA 
cells far of vessels, and low or negative expression in SEGA cells near the vessels. This particular expression 
pattern of both ABC-transporters, and CD34 antigen could identify different stem-cell subset in SEGA [69]. 
Similarly, co-expression of CD34 and neurofilament were described in epilepsy-associated glioneuronal 
tumors [62,70]. In normal brain, CD34 occurs only transiently during neurulation [71] and recently CD34 
immunoreactivity was also detected as a subpopulation of balloon cells confined to the white matter but 
not observed in neocortical layers from brain specimens of Taylor's focal cortical dysplasia [72]. 
Tissues from therapeutic resections of several refractory epilepsies, as dysembryoplastic neuroepithelial 
tumors, focal cortical dysplasia and hippocampal sclerosis, as well as several brain tumors as glial and 
glioneuronal tumors, are associated with pharmacoresistant epilepsy, having a much poorer 
pharmacological outcome compared to other symptomatic epilepsies. In all of them, overexpression of 
ABC-transporters as P-glycoprotein, MRPs and BCRP were described [10,24,45,69,73].  
ABC-transporters, particularly P-gp and BCRP, are transiently expressed at high levels in human neural 
stem/progenitor cells (hNSPCs) but are downregulated in differentiated hNSPCs, and in normal conditions, 
they are expressed in a highly regulated manner, with the highest expression in primitive cells and 
subsequent down-regulation following commitment to differentiation [74]. Furthermore, the constitutive 
deficiency of ABC-transporters leads to distinct impairments in neural stem/progenitor cells maturation 
and adult neurogenesis in vivo, indicating a functional role of ABC-transporters in stem cell maintenance 
and differentiation [75]. All these data clearly suggests that presence of ABC-transporters, in abnormal and 
immature brain cells as well as in immortalized tumor cells, are clearly a hallmark of a non-fully 
differentiated progenitor cell. If it is the case, ABC-transporters together other stem cell markers, could 
build a new biomarkers profile to give predictive information for long-term follow-up of surgically treated 
refractory epilepsies and/or related with the risk of relapse of seizures, even before that a new brain 
structural anomaly can be detected. Furthermore, at date, the available evidence demonstrates that long-
term seizure freedom is achieved in about 60% of patients who undergo temporal lobe surgery, and in 30–
40 % of those who undergo extratemporal surgery [76]. 
Conclusions 
It is important to distinguish between the truly drug-transporter properties of these proteins leading to 
the pharmacoresistant phenotype, from those related with plasmatic membrane depolarization inducing 
pro-epileptic effects, directly related with epileptogenesis as described for P-gp. In this sense, ABC-
transporters, as P-glycoprotein and BCRP, could be interpreted as stem-cell markers presents in several 
brain cortical malformations, being constitutive components of immature not-fully differentiated cells, as 
observed in dysplastic neurons and ballooned cells or brain tumor cells. Interestingly, all these abnormal 
cells that also play a role in the epileptogenesis, have high expression of ABC-transporters and are also 
refractory to AEDs. Under these conditions, repetitive seizures can induce simultaneous P-gp 
overexpression in both brain and heart. It could be a combined risk factor to develop an acute heart failure 
under severe stress triggered by status epilepticus resulting in a fatal end. 
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Finally, the condition of ABC-transporters as stem cell markers, if they are presents in those mentioned 
abnormal cells, could contribute to build a risk score or predictive profile for long-time seizures relapse 
after surgical treatment. 
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